Selskabets formål er at drive virksomhed inden for handel og industri.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 1.5 mia. | 64.5 mio. | 537.5 mio. | 173.2 mio. | 116 | |
CVR: 19248615
Secondary names: SYNTHES A/S, STRATEC MEDICAL A/S, Actelion A/S
Previous names: JANSSENPHARMA A/S
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Jesper Bilde Puck Nielsen joined the board
Julie Enevold Brooker left the board
Mikkel Dohm Johansen left the board
Companies in the same industry and area
CVR 45346951
CVR 19835081
CVR 21327581
CVR 46124723
CVR 19064301
JANSSEN-CILAG A/S demonstrates a solid financial health with a consistent upward trajectory in revenue and profit over the past few years. In 2024, the company reported revenue of 1.52 billion DKK and a profit of 64.47 million DKK, marking a notable increase from 1.43 billion DKK in revenue and 45.04 million DKK in profit in 2023. The equity position has also improved, rising to 173.24 million DKK, indicating a strengthening balance sheet. While profit margins appear stable, the company’s growth in the competitive pharmaceutical wholesale industry positions it favorably, though ongoing monitoring of market dynamics and operational efficiency will be essential for sustained success.
AI-generated summary
companydata.dk